Table 5 Characteristics of all studies reporting dichotomous outcomes (n = 52)
Variable | Median [25th, 75th Percentile] |
|---|---|
Sample Size | 113 [38, 230] |
Study Duration (weeks) | 13 [12, 17] |
Age | 41.1 [39.0, 42.2] |
% Female | 86.2% [81.6%, 88.5%] |
Median Improvement from Baseline in the Placebo Arm | 27.2 [16.1, 39.7] |
Placebo Route | N (%) |
 Oral | 23 (42.3%) |
 Injection | 22 (40.4%) |
 Intravenous | 6 (11.5%) |
 Unknown | 2 (5.8%) |
Cochrane Risk of Bias | |
 Low | 39 (75.0%) |
 Some Concerns | 8 (15.4%) |
 High | 5 (9.6%) |
Year of Publication | |
 1996 to 2004 | 10 (19.2%) |
 2005 to 2009 | 9 (17.3%) |
 2010 to 2014 | 5 (9.6%) |
 2015 to 2019 | 16 (30.8%) |
 2020 to 2021 | 12 (23.1%) |
Outcome Measure (% responder rate) | |
 Monthly migraine days | 26 (50.0%) |
 migraine headache days | 11 (21.2%) |
 attack frequency | 8 (15.4%) |
 migraine episodes per month | 0 (0.0%) |
 migraine days | 3 (5.8%) |
 headache attack frequency | 1 (1.9%) |
 headache days | 2 (3.9%) |
 intensity and duration | 1 (1.9%) |